Aragen appoints Aniel Khubchandani as CEO of Development and Manufacturing Solutions business
August 06, 2025
Hyderabad, India
Aragen, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the appointment of Aniel Khubchandani as CEO of its Development & Manufacturing Solutions business. Aniel will be a member of Aragen’s Management Council and will be based in Hyderabad.
Commenting on the appointment, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, said, “I am happy to welcome Aniel to Aragen and have him in the Management Council. Development and Manufacturing Solutions is a critical vertical with tremendous potential to significantly scale up. Aniel brings over 30 years of leadership experience in pharmaceuticals and specialty chemicals, with deep expertise in life sciences, commercial operations, and strategic initiatives, to lead this journey.”
Aniel Khubchandani said, “I am excited to join Aragen and lead its development and manufacturing business. Globally, there is an increasing focus on outsourcing, especially in the late phase and commercial manufacturing space. In the past few years, Aragen has made strategic investments to strengthen its capabilities and expand its capacity in the development and manufacturing vertical, and is on the cusp of scaling to the next level of growth. I thank the Board for giving me an opportunity to be a part of this exciting journey.”
Before joining Aragen, Aniel was the CEO of Sekhmet Pharmaventures and Co-CEO at Jubilant Ingrevia Limited, where he successfully led significant business transformations and growth strategies. His extensive experience includes organic growth initiatives, mergers & acquisitions, B2B digital marketing, enterprise risk management, licensing, and strategic execution. He is a certified Independent Director (IICA), a Six Sigma Black Belt, and an alumnus of IIT, IIM, and the Kellogg School of Management.
About Aragen: Aragen Life Sciences is a globally renowned R&D and manufacturing solutions provider to the global life sciences industries. It offers a range of solutions across the drug discovery, development and manufacturing continuum to advance small and large-molecule programs. The Company operates through a global network of six sites with a team of ~4500 employees and 450+ PhDs. Its expertise and experience have enabled over 400 customers to advance their research programs from early discovery through development and commercialization. Aragen’s innovative mindset, infrastructure, flexible business models, clear purpose, and proprietary project management platform have enabled it to effectively scale and service large pharma, biotech, agrochemical, and animal health industries globally. Visit www.aragen.com for more details.
Media Contact:
Aragen Life Sciences: Sandeep Nair, Sandeep.nair@aragen.com